Close

Bionor Pharma to initiate HIV Vacc-4x combination trial

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

New Data Shows Gazyva’s Superiority in Lupus Nephritis

The New England Journal of Medicine has published detailed...

Bionor Pharma is set to initiate a double blinded, randomized and placebo-controlled trial to evaluate HIV-vaccine candidate Vacc-4x in combination with Revlimid.Revlimid is indicated as a treatment for multiple myeloma and anemia due to myelodysplastic syndrome linked with a deletion in the long arm of the fifth chromosome. In the trial, around 12 patients will be given Vacc-4x in conjunction with Revlimid, however other set of 12 patients will receive Vacc-4x alone.The study aims to establish the ability of Vacc-4x in improving immune function in patients that fail to regain a healthy immune defense despite that their viral load is well controlled on conventional HIV-medicines (antiretroviral therapy – ART).

The study will also evaluate the effect of Revlimid on Vacc-4x’s ability to improve immune function.Bionor CSO Maja Sommerfelt said the use of a therapeutic vaccine combined with modulation of the immune system resonates well with the current thinking in the scientific community.

Latest stories

Related stories

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

New Data Shows Gazyva’s Superiority in Lupus Nephritis

The New England Journal of Medicine has published detailed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back